

## **TME PHARMA REPORTS ON END OF SIX-MONTH LOCK-UP PERIOD OF SHARES AND CONVERTIBLE BONDS FOLLOWING THE APRIL 2023 TRANSACTION**

**Berlin, Germany, October 17, 2023, 07.00 p.m. CEST – TME Pharma N.V. (Euronext Growth Paris: ALTME)**, a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the end of the six-month soft lock-up period of shares and the end of the lock-up of convertible bonds following the transaction announced on April 18, 2023.

As part of the April financing, 2,880,085 shares were issued and placed under a six-month soft lock-up. *TME Pharma* has been informed that during this period 2,305,000 shares were placed on the market at an average price of €1.43, i.e., 80% of the total of the issued shares. In parallel none of the 2,348 currently outstanding convertible bonds, including interest, have been converted.

The characteristics, terms and conditions of the April transaction can be found in the press release dated April 18, 2023, and the overview of the convertible bonds on the "[Documentation](#)" page of the company's website in the "Financing Instruments" section.

### **For more information, please contact:**

#### **TME Pharma N.V.**

Aram Mangasarian, Ph.D., CEO  
Tel. +49 (0) 30 726247 0  
[investors@tmepharma.com](mailto:investors@tmepharma.com)

### **Investor and Media Relations:**

#### **LifeSci Advisors**

Guillaume van Renterghem  
Tel. +41 (0) 76 735 01 31  
[gvanrenterghem@lifesciadvisors.com](mailto:gvanrenterghem@lifesciadvisors.com)

#### **NewCap**

Arthur Rouillé  
Tel. +33 (0) 1 44 71 00 15  
[arouille@newcap.fr](mailto:arouille@newcap.fr)

## About TME Pharma

*TME Pharma* is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company's oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME, *TME Pharma's* approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. In the GLORIA clinical trial, *TME Pharma* is studying its lead drug candidate NOX-A12 in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. *TME Pharma* has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA expansion arms evaluate safety and efficacy of NOX-A12 in other combinations where the interim results from the triple combination of NOX-A12, radiotherapy and bevacizumab suggest even deeper and more durable responses, and improved survival. NOX-A12 in combination with radiotherapy has received orphan drug designation for glioblastoma in the United States and glioma in Europe. *TME Pharma* has delivered final top-line data with encouraging overall survival and safety profile from its NOX-A12 combination trial with Keytruda® in metastatic colorectal and pancreatic cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered in its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck's Keytruda® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The design of the trial has been approved in France, Spain and the United States. The company's second clinical-stage drug candidate, NOX-E36, is designed to target the innate immune system. *TME Pharma* is considering several solid tumors for further clinical development. Further information can be found at: [www.tmepharma.com](http://www.tmepharma.com).

*TME Pharma*® and the *TME Pharma* logo are registered trademarks.

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.

Visit *TME Pharma* on [LinkedIn](#) and [Twitter](#).

## About the GLORIA Study

GLORIA (NCT04121455) is *TME Pharma's* dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 three additional arms combining NOX-A12 with: A. radiotherapy in patients with complete tumor resection; B. radiotherapy and bevacizumab; and C. radiotherapy and pembrolizumab.

## About the OPTIMUS Study

OPTIMUS (NCT04901741) is *TME Pharma's* planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

**Disclaimer**

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements." Forward-looking statements are based on *TME Pharma's* current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and *TME Pharma's* ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and *TME Pharma* undertakes no duty to update such information except as required under applicable law.